当前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 78611Anti-CD20 CAR-T Cells
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
The anti-CD20 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD20 CAR Lentivirus (CD20 ScFv-CD8-4-1BB-CD3ζ; BPS Bioscience #78606). These ready-to use CAR-T cells express an anti-CD20 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1).
These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.
Figure 1: Construct diagram showing components of the anti-CD20 CAR expressed in anti-CD20 CAR-T cells.
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,化工仪器网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。